INTRODUCTION

Beh?et’s disease (BD) was first discovered by Hulusi Beh?et

. The geographical distribution of BD is related to the Silk Road rout. The disease is widespread in Middle Eastern,Far Eastern and Mediterranean countries such as Iran, Turkey,Tunisia, China, and Japan

. The highest incidence of BD is in Turkey (80 to 370 patients per 100 000 population). The prevalence of the disease in Japan is about 13.5 per 100 000 and in Iran 80 per 100 000

. It is a vasculitis associated with oral and genital ulcers, skin lesions and ocular involvement

.Ocular involvement is in the form of recurrent non-granulomatous uveitis that can affect the anterior and posterior chambers of the eye. Uveitis is usually bilateral

. However, the intestine and the central nervous system can also be affected

.

Management and treatment of BD is a serious challenge due to different clinical aspects. Therefore, treatment should be proportional to the patient’s condition and severity of clinical symptoms

. Colchicine and non-steroidal anti-inflammatory drugs are often used to treat joint and mucosal involvement.However, more aggressive methods and immune suppressive agents are needed to treat severe symptoms such as uveitis,retinal vasculitis, neurological and gastrointestinal involvement

.Current treatment focuses on reducing inflammation and controlling the immune system. For severe manifestation of the disease, high dose corticosteroids are used

.

第一，在招投標(biāo)階段，招標(biāo)單位要保證招標(biāo)程序合法公平，盡量選擇信譽(yù)度高、技術(shù)過硬、有實(shí)力且報(bào)價(jià)相對(duì)較低的建設(shè)施工單位，嚴(yán)禁通過不合理方式獲取工程承包權(quán)及濫用私權(quán)行為的出現(xiàn)。第二，在工程建設(shè)過程中，承包商要結(jié)合施工合同的各項(xiàng)條款，采取科學(xué)有效的施工進(jìn)度管理措施，加強(qiáng)對(duì)分包事項(xiàng)等的監(jiān)督管理，同時(shí)監(jiān)理方要充分體現(xiàn)出自身的監(jiān)督職能作用，強(qiáng)化管理與控制，確保工程建設(shè)的順利開展。第三，在竣工驗(yàn)收階段，要根據(jù)合同約定的工程數(shù)量與質(zhì)量，并結(jié)合相關(guān)標(biāo)準(zhǔn)進(jìn)行驗(yàn)收，確保工程質(zhì)量的合格，防止因質(zhì)量不合格出現(xiàn)返工，甚至安全危險(xiǎn)因素等，進(jìn)而影響工程按期交付使用情況的發(fā)生。

BD patients have high levels of proinflammatory cytokines such as IL-1, IL-2, IL-6, tumor necrosis factor (TNF-α), IL-12,IL-17, IL-18, and IL-23R

. TNF-α is an inflammatory cytokine that plays a role in homeostasis and immune response and in fact, it plays a major role in autoimmune diseases pathogenesis

. This cytokine is encoded in the class 3 region of the HLA complex adjacent to HLA-B

. TNF-α is secreted by many types of cells such as macrophages,monocytes and lymphocytes

. Anti-TNF drugs are a group of medications that suppresses the physiologic response to

隨著油田企業(yè)業(yè)務(wù)的開展，檔案資料的內(nèi)容也逐漸增加，給檔案管理工作帶來了更高的難度。此外，對(duì)于油田企業(yè)的檔案來說，不僅僅需要做好保存工作，而且要挖掘檔案的潛在價(jià)值，為當(dāng)前工作更高質(zhì)量、更高效率地開展提供必要的借鑒。而這些工作的開展，都離不開一套完善的檔案信息化管理制度。由于油田企業(yè)對(duì)于檔案管理工作重視不足，配套的信息化管理制度也沒有建立起來。有些企業(yè)即便是有檔案信息化數(shù)據(jù)運(yùn)行管理制度，在實(shí)際工作中沒有嚴(yán)格執(zhí)行，管理制度形同虛設(shè)，檔案管理人員工作中存在較大的隨意性。

TNF-α. The medications in this class include infliximab,etanercept, adalimumab, certolizumab pegol and golimumab.Infliximab, adalimumab, and golimumab are monoclonal antibodies against TNF-α. Etanercept is a soluble, divalent TNF-α receptor that binds to TNF-α to prevent it from binding to its receptor on the cell. Certolizumab pegol is the antigenbinding fragment (Fab’) of a humanized monoclonal antibody that has been conjugated to polyethylene glycol. Induction of antibodies against TNF is largely dependent on its structure,chimeric drugs have a higher capacity to stimulate the immune system than human drugs

.

The essential purposes in the management of patients with Beh?et’s uveitis are fast elimination of visual inflammation,avoidance of recurrent attacks, getting of whole remission,and maintenance of vision. Corticosteroids are generally used for the treatment of episodes of inflammation; however, their long-term use is associated with unacceptable side effects.Relapses are normal in the setting of steroid mono-therapy,and conventional immunosuppressive drugs have usually been used for long-term treatment

.

The combination of azathioprine and cyclosporine is more impressive than is immunotherapy with either factor, or combination therapy is used as a severe immunosuppressive regimen for the treatment of patients with severe Beh?et’s uveitis

. In addition, we did not find any studies comparing infliximab with steroids. However, in some studies, infliximab was compared with cyclosporine, and the results showed that following the use of infliximab, the conditions of ocular inflammation were greatly reduced

.

Anti-TNF drugs that has been approved for treatment of rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis and has been used for the treatment of uveitis in BD with promising results

. In general, anti-TNFs such as infliximab have been used to treatment uveitis, and anti-TNFs such as etanercept have been used to treat skin lesions

. Some studies have suggested that long-term use of biologic drugs can lead to infection in some patients. However, some other studies have shown that no side effects lead to infection of the skin, soft tissues and joints

. In some other studies, it has been reported to cause cancer in people who have taken these drugs for a long time. But in general, none has been proven

.However, due to inconsistent results of the present studies and the lack of systematic study, this study is intended to evaluate the therapeutic effects of anti-TNF agents in BD patients with ocular involvement.

MATERIALS AND METHODS

After determining the search keywords,including Beh?et’s disease, Beh?et’s syndrome, adamantiades-Beh?et’s disease, anti-TNF agents and uveitis, they were searched both using MeSH keywords and freely in the databases of MEDLINE, Scopus, CINHAL, Psycoinfo,Cochrane Library, Proquest. Iranmedex, SID, IranDoc, Magiran databases were also searched for information in Persian. In addition to the above databases, the list of selected study resources as well as related conferences was searched manually.

早白堊世華北克拉通東部進(jìn)入破壞峰期，淺部地質(zhì)以伸展活動(dòng)為特征，廣泛出現(xiàn)斷陷盆地，而深部過程以巖石圈轉(zhuǎn)型與減薄為特征，主要表現(xiàn)形式為巖漿活動(dòng)[18]。

All articles were searched until May 2020 and studies were included in our research that met the inclusion criteria and included: 1) were published by May 2020; 2) studies were designed pre and post anti-TNF drug treatment; 3) were consistent in terms of keywords (in the field of BD, anti-TNF drugs, visual acuity, conflict and ocular attack); 4) contained information of the original article type; 5)had sufficient information such as best-corrected visual acuity(BCVA) or decimal or visual acuity logMAR score.

Exclusion criteria also included: 1) in terms of keywords in the title and abstract screening stage did not match; 2) review and duplicate studies were excluded; 3) studies unrelated to Beh?et and eye involvement and lacked visual acuity score; 4) nonhuman studies (for example in the mouse).

After identifying the final articles, the articles were sorted by publication date. Before extracting the data,the tables required for this study were designed based on the required criteria in the extraction table in excel software environment. Then, two authors separately and independently extracted the required data from the final selected articles based on pre-prepared tables.

馬鈴薯品種、種植地土壤營(yíng)養(yǎng)、栽植方式等均會(huì)對(duì)播種密度產(chǎn)生直接影響，而播種密度又會(huì)直接影響馬鈴薯的產(chǎn)量及品質(zhì)。通常情況下早熟型馬鈴薯品種播種密度要稍大于晚熟型品種，育種馬鈴薯密度要高于商品馬鈴薯；制作淀粉的種植密度要大于制作薯?xiàng)l的種植密度。

According to the contents mentioned in this section, in the first stage after the initial search, the number of articles included in the study was 1504, of which 523 were duplicate articles(981 articles remaining). Finally, according to the mentioned criteria, only 15 articles were found to be completely relevant,of which 12 articles were included in the analysis related to the visual acuity criterion (Figure 1).

The visual prognosis in BD is affected by severe recurrence of uveitis. Recurrent attacks of ocular inflammation lead to structural changes that may lead to visual impairment and even blindness in patients if not treated promptly and appropriately. The main goal of Beh?et’s uveitis management is to quickly eliminate inflammation inside the eye, prevent recurrent attacks and maintain vision in these patients. TNF-α is a factor that plays a pivotal role in the development and maintenance of the inflammatory response, even though the specific etiopathogenesis of BD has not yet been elucidated but many experimental studies have shown that TNF-α plays an important role in the progression and persistence of ocular inflammation in BD

. Therefore, in order to better understand which anti-TNF drugs have an effective therapeutic role in BD, we conducted this systematic review and Metaanalysis of data and pooled results.

After fully extracting the data related to our articles, it was found that only the visual acuity index has been reported in most articles and is common to them and we lastly selected this index for the Meta-analysis. Finally, in case of discrepancies between the data, it was discussed until the same result was reached.

We assessed the quality of the involved studies using the Cochrane Collaboration’s tool for assessing the risk of bias

. In this reading, selected studies were judged based on the following criteria: bias related to patient selection (“selection bias”) which is determined based on the complete description of patient selection and their inclusion and exclusion criteria. If patients are carefully selected, they will be considered low risk in terms of bias risk. Measurement bias, which in this study is related to methods of measuring ocular involvement and ocular inflammation and score related to visual acuity. If precise methods are used, the risk is considered low. Follow-up bias, which refers to the length of the follow-up period. If it is mentioned in full detail, the risk is low in terms of bias. Exposure bias was considered as changes in ocular inflammation in patients. If the values related to visual acuity, eye inflammation and eye attacks are reported with great accuracy, it is reported as low risk. Finally,confounding bias is related to the data analysis and results.If the confounding factors such as gender, age, and drug use are carefully observed during the analysis of visual acuity and other factors related to eye inflammation, that study is considered low risk in confounding bias.

We measured risk of bias using the Cochrane Collaboration’s tool for measuring the risk of bias in randomized trials. We classified bias according to five domains: sample selection bias, measurement bias, follow-up bias, exposure (ocular response) bias, and confounding (correlation) bias. We defined risk of bias as low, high, unclear risk. In most of the studies we reviewed, the inclusion and exclusion criteria were clearly mentioned, and most of them were in the low group. Most studies on the method section and method of assessment the severity of ocular inflammation and visual acuity score were fully explained. Therefore, these options were placed in the low-risk bias group.

RESULTS

Findings from Systematic Review

After systematic review of articles,according to inclusion and exclusion criteria, finally 15 related articles were found, of which 12 articles were included in the Meta-analysis. One study was conducted in the Africa, six studies in European countries, and eight study in Asia. Of the 15 articles found, 9 articles examined the effect of infliximab and 4 articles about adalimumab and two others as a combination of two drugs. In these studies, the dose of infliximab was 5 mg/kg and adalimumab was 40 mg/subcutaneous/2wk. The mean age of the samples was 31.0y and the mean duration of illness and follow-up were 7.88y and 16.72wk, respectively. In these studies, the average duration of use of biological drugs was 18.21mo. The mean dose of prednisolone before and after biological treatments was reported in 5 studies and was 28.56 and 7.56 mg/kg, respectively.

The electronic search, conducted until May 2020, resulted in 1458 abstracts, of which 378 abstracts were reviewed. Of those, 118 full texts were read and 15 found to be eligible (of these, 15 articles were selected for systematic review and among them 12 articles had the necessary properties for Meta-analysis). The reference lists of all 12 case-control were searched for relevant articles. Full texts of the major reviews found were read and their reference lists searched. The study characteristics of the patients enrolled in these studies are summarized in Table 1

.

Data for this study were extracted using a pre-designed table. Then, using comprehensive Metaanalyzed CMA.2 software, the data were analyzed by random effect method and the heterogeneity of the studies and their distribution was evaluated and Forrest plot and Funnel plot diagrams were presented.

The studies also showed that the follow-up range and length of patients is either fully explained or incomplete. Because of this, they were either low or high risk in terms of followup bias. The bias of ocular response (exposure bias) was fully focused in most studies. Therefore, the bias of this option was considered low risk. Finally, in most studies, confounding factors such as gender, age, and medication use were carefullyconsidered during the analysis of visual acuity and other factors associated with ocular inflammation. For this reason,in most of them, low-risk bias was considered. The risk of bias in each included study is summarized in Table 2 and Figure 2.

The articles and documents obtained from the search were screened in several stages in terms of title, abstract and full text, and the final studies with inclusion criteria were selected.The studies were evaluated by 2 experts and using a checklist(PRISMA) in terms of the types of bias risks (selection,performance, report, attrition,

.) as well as content, critique and low-quality studies were discarded. Also, in case of disagreement between the experts, the third person was used and a group discussion was held. Relevant data were then extracted from the studies using a designed table.

Data was entered in Comprehensive Meta-Analysis (CMA) 2.2 (BioStat Inc., US)and random-effect models were used. Assessment of risk of bias in included studies has been considered. The visual acuity logMAR score as the primary outcome variable was expressed as continuous variables. Standard deviation was calculated using actual

-values obtained from

-tests quoted by Cochrane. For every study, we calculated the mean difference(MD) for the primary outcome visual acuity logMAR score using 95% confidence interval (95%CI). The outcome measures were pooled by use of the random-effect model.Heterogeneity was calculated using Cochrane’s

statistic and quantified using the

statistic. These indicated the proportion of variability across studies due to heterogeneity, rather than sample error. In the case of missing data, efforts to contact authors were made.

把握了上述三類“道”義，我們不難看出作者的思想，這有助于對(duì)“道”的英譯。然而，文中“道”的含義廣博，尤其是儒道之“道”，很難在英語(yǔ)世界找到相應(yīng)的對(duì)應(yīng)詞，獲得傳神達(dá)意的得體譯本。筆者姑且選取劉師舜、楊憲益、戴乃迭夫婦以及羅經(jīng)國(guó)這三個(gè)經(jīng)典譯本（以下分別簡(jiǎn)稱劉譯、楊譯、羅譯），將對(duì)應(yīng)的“道”的譯文摘出，按上文“道”的釋義及分類順序分別列舉如下（粗體為筆者所加）：

Asymmetry assessment of the funnel plot was con ducted for publication bias only to showcase the sample interventions.There was a slight asymmetry in Begg’s funnel plot, we did not find any evidence of publication bias for visual acuity logMAR (Egger’s test

=2.54,

=0.05, Begg’s test

=0.6,

=0.54; Figure 4).

The preliminary results indicate a nonsignificant reduction in visual acuity logMAR score (MD=-1.5 IU/L, 95%CI:-2.1, -0.01). However, significant heterogeneity was revealed among studies (

=154.97,

=92.9%,

＜0.001). Despite a high

, results were pooled, as examination of these studies on a Forest plot indicated that the individual trial results were consistent in the direction of the effect (

, MD and confidence intervals largely fell on one side of the null line;Figure 3). Characteristics of age, sex ratios, and baseline visual acuity were similar across all trials. Table 1 highlights the characteristics of the included studies.

DISCUSSION

These data include general data of articles (name of the first authors of the articles, name of the country of study, year of study, sample size, age of individuals, length of treatment,and length of follow-up), data related to interventions (type of drug used, drug dose, names of other drugs (steroid and nonsteroidal drugs), response data (BCVA score, ocular attacks,prednisolone dose pre and post anti-TNF drug used).

由于本工程地下水位位于樁底以上，全干孔作業(yè)需要先行降低地下水位，實(shí)施難度大，成本花費(fèi)高，安全系數(shù)低，故不予考慮；濕孔作業(yè)能達(dá)到施工要求，但近年來，鄭州市環(huán)保要求高，鉆孔泥漿造成大量污染，儲(chǔ)存及運(yùn)輸難度大，不利于環(huán)境治理。故綜合考慮選擇半濕孔鉆孔作業(yè)，既加快了進(jìn)度，減少了投入，又有利于環(huán)境治理。

The TNF-α is a pro-inflammatory cytokine which can adjust immune cells’ activity in autoimmune diseases. Since BD is a kind of autoimmune disease, therefore, TNF-α plays a significant role in causing inflammation in BD

. Research shows that high levels of TNF-α and its receptors are present in the serum or plasma of BD patients along with other proinflammatory cytokines

. Accordingly, blocking the TNF-α pathway can be considered as the first or second-line valid treatment in BD patients with ocular symptoms and uveitis. Anti-TNF drugs as a new therapeutic approach are the strategic alternative to traditional safety immunosuppressant

while the results of infliximab have been very encouraging for the treatment of severe uveitis in BD

.

(3)洗胃后心里護(hù)理。首先,為患者創(chuàng)造一個(gè)良好的病房環(huán)境,保護(hù)其隱私。同時(shí),安排家屬在身邊陪伴;其次,與患者采取一對(duì)一溝通模式,引導(dǎo)患者將內(nèi)心情緒全面化表達(dá)出來,做深入化心理疏導(dǎo)。幫助患者正確認(rèn)知自己,以采用積極的心態(tài)面對(duì)問題,提高其心理承受力、社會(huì)適應(yīng)力;

The researchers showed that anti-TNF-α regulates peripheral blood CD4+ T cells in patients with posterior intraocular inflammation, which is associated with improved visual function. In one study, researchers have been found that infliximab injections in patients with BD reduced the number of TNF-secreting peripheral blood mononuclear cells

, which in turn reduced eye attacks and improved vision in patients

.

This study confirmed the efficacy of anti-TNF therapy (infliximab or adalimumab) for treating refractory uveitis associated with BD. Also, the results related to the number of ocular inflammatory attacks in these patients have been shown that the number of attacks after the addition of biological anti-TNF therapies has decreased significantly as shown in earlier studies. Since the use of some drugs can interfere with the results of the study, so these studies were not included in the results and were excluded from our study. However, in most studies, patients have used the same drugs to treat the disease, and in the end, only the results of prednisolone,which had a decreasing trend, have been reported in some studies

. The results of some previous studies on the effects of these drugs may seem contradictory. One of the main reasons for the contrary results of the studies may be due to the fact that the patients studied in this research used different immunosuppressive drugs, some patients have used corticosteroids, and others have used drugs such as colchicine,azathioprine, and cyclosporine. Also, the dose and duration of drugs use have varied in different people, and all of these can affect the final results of these studies. In general, most treatments are used to reduce the dose of steroid drugs, which these drugs (anti-TNF) have also been associated with a significant reduction in the use of steroid drugs.

為貫徹落實(shí)《國(guó)家信息化發(fā)展戰(zhàn)略綱要》《“十三五”國(guó)家信息化規(guī)劃》《全國(guó)司法行政“十三五”發(fā)展規(guī)劃》，全面推進(jìn)司法行政信息化建設(shè)發(fā)展，司法部于2017年7月12日發(fā)布的《關(guān)于印發(fā)〈“十三五”全國(guó)司法行政信息化發(fā)展規(guī)劃〉的通知》（司發(fā)通［2017］75號(hào)），明確提出司法鑒定管理信息化的管理要求。因此司法鑒定機(jī)構(gòu)信息化建設(shè)是響應(yīng)國(guó)家司法行政信息化發(fā)展的要求。對(duì)于緊跟司法行政管理政策，提高機(jī)構(gòu)鑒定質(zhì)量和效率，增強(qiáng)鑒定機(jī)構(gòu)管理和服務(wù)能力，促進(jìn)信息公開和社會(huì)監(jiān)督，具有十分重要的意義。

One of the main limitations of this study may be the relatively low sample size in the studies. Other limiting factors include confounding factors such as patients’ age, medications used,type of medication, and dose of medication before biological drugs are added. However, in some studies, these factors were considered as confounders and the final results were reported.In conclusion, however, the overall results of this study show that the use of biologic drugs (anti-TNF drugs) along with other therapeutic drugs, has been effective on patients’ visual acuity and has led to a significant improvement in them.Also, the amount of eye attacks in them has been significantly reduced. In addition, since the long-term use of corticosteroid drugs can be harmful, simultaneous use of biological drugs can reduce the dose of prednisolone.

長(zhǎng)石礦物量較少(<5%)，但礦物種類繁多，主要為鉀長(zhǎng)石，偶見有條紋長(zhǎng)石、微斜長(zhǎng)石和鈉長(zhǎng)石等?，F(xiàn)主要對(duì)鉀長(zhǎng)石的嵌布特征描述如下：

None;

None;

None;

None;

None.

1 Bulur I, Onder M. Beh?et disease: new aspects.

2017;35(5):421-434.

2 Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH.Epidemiology of Beh?et disease.

2012;20(5):324-335.

3 Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E,Inanc M, Gül A. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine,cyclosporine, and corticosteroids in Beh?et’s disease: an open-label trial.

2005;52(8):2478-2484.

4 Fabiani C, Sota J, Vitale A,

. Cumulative retention rate of adalimumab in patients with Beh?et’s disease-related uveitis: a fouryear follow-up study.

2018;102(5):637-641.

5 Lopalco G, Emmi G, Gentileschi S,

. Certolizumab Pegol treatment in Beh?et’s disease with different organ involvement: a multicenter retrospective observational study.

2017;27(6):1031-1035.

6 Vallet H, Riviere S, Sanna A,

Efficacy of anti-TNF alpha in severe and/or refractory Beh?et’s disease: multicenter study of 124 patients.

2015;62:67-74.

7 Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H. A double-blind trial of depot corticosteroids in Beh?et’s syndrome.

(

) 2005;45(3):348-352.

8 Mendes D, Correia M, Barbedo M,

. Beh?et’s disease - a contemporary review.

2009;32(3-4):178-188.

9 Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Beh?et’s disease.

2012;11(10):699-704.

10 Dilek K, Oz?imen AA, Saricao?lu H, Saba D, Yücel A, Yurtkuran M,Yurtkuran M, Oral HB. Cytokine gene polymorphisms in Beh?et’s disease and their association with clinical and laboratory findings.

2009;27(2 Suppl 53):S73-S78.

11 Alipour S, Nouri M, Khabbazi A, Samadi N, Babaloo Z, Abolhasani S,Farhadi J, Roshanravan N, Jadideslam G, Sakhinia E. Hypermethylation of IL-10 gene is responsible for its low mRNA expression in Beh?et’s disease.

2018;119(8):6614-6622.

12 Abolhasani S, Gholizadeh Ghaleh Aziz S, Khabbazi A, Alipour S.Determination of the relationship between the severity of Beh?et’s disease and the expression and methylation of IL-10, IL-6 and IL-8 genes.

2018;4(1):6-14.

13 Alipour S, Sakhinia E, Khabbazi A,

. Methylation status of interleukin-6 gene promoter in patients with Beh?et’s disease.

(

) 2020;16(3):229-234.

14 Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Beh?et’s disease, sarcoidosis, and noninfectious uveitis.

2013;2013:286857.

15 Aziz SGG, Aziz SGG, Khabbazi A, Alipour S. The methylation status of

-α and

promoters and the regulation of these gene expressions in patients with Beh?et’s disease.

2020;25(5):384-390.

16 Ate? A, Kinikli G, Düzgün N, Duman M. Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Beh?et’s disease.

2006;26(4):348-353.

17 Emi Aikawa N, Carvalho JF, Artur Almeida Silva C, Bonfá E.Immunogenicity of anti-TNF-α agents in autoimmune diseases.

2010;38(2-3):82-89.

18 Kaklamani VG, Kaklamanis PG, editors.

—

Elsevier; 2001.

19 Hasanreisoglu M, Cubuk MO, Ozdek S, Gurelik G, Aktas Z,Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory beh?et uveitis.

2017;25(1):71-75.

20 Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M.Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh?et disease.

2010;94(3):284-288.

21 Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS.Infliximab therapy for the treatment of refractory ocular inflammatory disease.

2007;125(7):895-900.

22 Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-tnf therapy in Crohn’s disease.

2018;19(8):2244.

23 Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P,Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh?et’s disease.

2001;358(9278):295-296.

24 Atzeni F, Gianturco L, Talotta R, Varisco V, Ditto MC, Turiel M,Sarzi-Puttini P. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?

2015;7(4):353-361.

25 Ding TN, Deighton C. Complications of anti-TNF therapies.

2007;2(6):587-597.

26 Higgins JP, Thomas J, Chandler J,

.

. John Wiley & Sons; 2019.

27 Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C,Cimino L, Gini G, Lenzetti I, Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Beh?et’s disease: a 24-month followup study.

(

) 2007;46(7):1161-1164.

28 Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G.One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh?et’s disease refractory to standard immunosuppressive drugs.

2011;31(1):33-37.

29 Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H,Fujino Y. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.

2012;56(6):536-543.

30 Fabiani C, Vitale A, Emmi G,

. Efficacy and safety of adalimumab in Beh?et’s disease-related uveitis: a multicenter retrospective observational study.

2017;36(1):183-189.

31 Al Rashidi S, Al Fawaz A, Kangave D, Abu El-Asrar AM. Longterm clinical outcomes in patients with refractory uveitis associated with Beh?et disease treated with infliximab.

2013;21(6):468-474.

32 Ho M, Chen LJ, Sin HPY, Iu LPL, Brelen M, Ho ACH, Lai TYY,Young AL. Experience of using adalimumab in treating sightthreatening paediatric or adolescent Beh?et’s disease-related uveitis.

2019;9(1):14.

33 Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R,Neumann R, Kramer M. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.

2018;256(4):801-808.

34 El Garf AK, Shahin AA, Shawky SA, Azim MA, Effat DA,Abdelrahman SK. Efficacy of infliximab in refractory posterior uveitis in Beh?et's disease patients.

2018;40(2):93-97.

35 Interlandi E, Leccese P, Olivieri I, Latanza L. Adalimumab for treatment of severe Beh?et’s uveitis: a retrospective long-term followup study.

2014;32(4 Suppl 84):S58-S62.

36 Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H. Health- and vision-related quality of life in patients receiving infliximab therapy for Beh?et uveitis.

2013;97(3):338-342.

37 Ueda S, Akahoshi M, Takeda A,

. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Beh?et’s disease.

2018;5(1):9-15.

38 Bawazeer A, Raffa LH, Nizamuddin SHM. Clinical experience with adalimumab in the treatment of ocular Beh?et disease.

2010;18(3):226-232.

39 Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh?et’s disease on infliximab therapy.

2011;95(9):1245-1250.

40 Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V,

. Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh?et’s disease: national multicenter study of 177 cases.

2019;71(12):2081-2089.

41 Hu YW, Huang ZH, Yang SZ, Chen XQ, Su WR, Liang D.Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in Beh?ets’ disease-associated uveitis: a systematic review and meta-analysis.

2020;11:941.

42 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis.

2015;60(6):575-589.

43 Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S,Hamuryudan V, Yazici H. Short-term trial of etanercept in Beh?et's disease: a double blind, placebo controlled study.

2005;32(1):98-105.

44 Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

2007;56(10):3248-3252.

45 Iwata D, Namba K, Mizuuchi K, Kitaichi N, Kase S, Takemoto Y,Ohno S, Ishida S. Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh?et’s disease with infliximab.

2012;250(7):1081-1087.

46 Adán A, Hernandez V, Ortiz S, Molina JJ, Pelegrin L, Espinosa G, Sanmartí R. Effects of infliximab in the treatment of refractory posterior uveitis of Beh?et’s disease after withdrawal of infusions.

2010;30(5):577-581.

47 Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y. Cytokine production profile in patients with Beh?et’s disease treated with infliximab.

2003;24(5):210-218.